NFE2L2 and non-small cell lung carcinoma: * “Treatment with NRF2 inhibitor, brusatol, increased the sensitivity of NSCLC cells to erastin-induced ferroptosis in vitro and in vivo, which depended on the upregulation of FOCAD partially”* “Brusatol can enhance the efficacy of chemotherapy via inhibiting NRF2 signaling pathway”